Disease-specific and patient-reported outcomes under active surveillance.
OBJECTIVE
To give insight into literature from the past 12-18 months, reporting on disease-specific and patient-reported outcomes of men under active surveillance for prostate cancer.


RESULTS
From recently published established active surveillance cohorts, we learnt that medium and long-term follow-up outcome data provide favorable evidence for the feasibility and safety of active surveillance. The mortality rates reported are consistent with expected mortality in favorable-risk patients who were managed with initial radical therapy. More definite conclusions on the safety of active surveillance can only be drawn on the basis of randomized controlled trial data. With respect to quality of life, men on active surveillance seem to do well, also with respect to urinary and erectile function. Further research on this subject is, however, warranted.


CONCLUSIONS
Prostate cancer-specific mortality under active surveillance is very low. The combination of disease-specific and patient-reported outcomes indicates that active surveillance is feasible. This is also reflected in smaller, population-based studies which confirm the acceptance of active surveillance in clinical practice.
aErasmus University Medical Center, Department of Urology bErasmus University Medical Center, Department of Public Health, Rotterdam, The Netherlands.
Lionne D F
LD
Venderbos
Chris H
CH
Bangma
Ida J
IJ
Korfage
D018450:Disease Progression; D006801:Humans; D008297:Male; D063868:Patient Outcome Assessment; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011788:Quality of Life; D057832:Watchful Waiting
D017430:Prostate-Specific Antigen